ClinicalTrials.gg
CompletedNCT04797715ACCORDUpdated Nov 29, 2023

Assessing Clinical Outcomes in Alzheimer's Disease Agitation

A Phase 3 interventional study of AXS-05 and Placebo in Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease and Agitation,Psychomotor, sponsored by Axsome Therapeutics, Inc.. Completed at 63 sites in 2 countries. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2022, 3 years 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2023.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
65 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,942 studies in Alzheimer Disease with a site in United States — 348 open to participants now, 447 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
481st of 1,611
178 · median 73
Started
2020
with 103 others
Phase 3
188 of 1,942
19 open now
Registered
1,304th of 1,942
by date

Among the 1,942 studies in Alzheimer Disease with a site in United States, this one is the 481st largest by enrollment of the 1,611 interventional ones that give a count, is one of 104 that started in 2020, is one of 188 in phase 3, and was the 1,304th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

348 of the 1,942 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

343 more — sign in →

All 348 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 65 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,942 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, double-blind, placebo-controlled, randomized withdrawal study to evaluate the efficacy and safety of AXS-05 compared to placebo in the treatment of agitation symptoms in subjects with agitation associated with Alzheimer's disease.

Read the detailed description

Enrolled patients will first enter a 9-week, open-label stabilization period, during which they will be treated with AXS-05 and monitored for a treatment response. Patients who experience a treatment response during the stabilization period will then be randomized into the double-blind treatment period, in a 1:1 ratio, to continue treatment with AXS-05 or to switch to placebo, for up to 26 weeks or until a relapse of agitation occurs.

03

Conditions studied

  • Agitation in Patients With Dementia of the Alzheimer's Type
  • Alzheimer Disease
  • Agitation,Psychomotor

Keywords

  • AD agitation
  • AXS-05
  • NMDA receptor antagonist
  • dextromethorphan
  • bupropion
  • Axsome
  • ACCORD
04

Who can participate

Ages eligible
65 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria.
  • Diagnosis of clinically signification agitation resulting from probable AD according to the International Psychogeriatric Association (IPA) provisional definition of agitation.

Exclusion criteria

Exclusion Criteria:

  • Patient has dementia predominantly of non-Alzheimer's type.
  • Patient has symptoms of agitation that are not secondary to AD (e.g., pain, other psychiatric disorder or delirium due to a metabolic disorder, systemic infection, or substance-induced).
  • Unable to comply with study procedures.
  • Medically inappropriate for study participation in the opinion of the investigator.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    AXS-05

    Up to 26 weeks in double-blind period

    Drug: AXS-05

  • Placebo comparator
    Placebo

    Up to 26 weeks in double-blind period

    Drug: Placebo

Interventions

  • DrugAXS-05

    AXS-05 tablets, taken twice daily

  • DrugPlacebo

    Placebo tablets, taken twice daily

06

What researchers measure

Primary outcomes

  1. Time from randomization to relapse of agitation symptoms

    Time frame: up to 26 weeks

Other outcomes

  1. Types and rates of adverse events

    Time frame: up to 35 weeks

07

Study locations

63 sites
  • Clinical Research Site
    Sun City, Arizona 85351, United States
  • Clinical Research Site
    Tucson, Arizona 85710, United States
  • Clinical Research Site
    Chula Vista, California 91910, United States
  • Clinical Research Site
    Imperial, California 92251, United States
  • Clinical Research Site
    Lafayette, California 94549, United States
  • Clinical Research Site
    Los Alamitos, California 90720, United States
  • Clinical Research Site
    Los Angeles, California 90064, United States
  • Clinical Research Site
    Oceanside, California 92056, United States
  • Clinical Research Site
    San Diego, California 92103, United States
  • Clinical Research Site
    Santa Ana, California 92705, United States
  • Clinical Research Site
    Temecula, California 92591, United States
  • Clinical Research Site
    Coral Springs, Florida 33067, United States
  • Clinical Research Site
    Hialeah, Florida 33012, United States
  • Clinical Research Site
    Kissimmee, Florida 34741, United States
  • Clinical Research Site
    Lake City, Florida 32055, United States
  • Clinical Research Site
    Miami Lakes, Florida 33014, United States
  • Clinical Research Site
    Miami, Florida 33155, United States
  • Clinical Research Site
    Miami, Florida 33175, United States
  • Clinical Research Site
    Miami, Florida 48532, United States
  • Clinical Research Site
    Naples, Florida 34105, United States
  • Clinical Research Site
    Ocoee, Florida 34761, United States
  • Clinical Research Site
    Orlando, Florida 32807, United States
  • Clinical Research Site
    Orlando, Florida 32819, United States
  • Clinical Research Site
    Pembroke Pines, Florida 33024, United States
  • Clinical Research Site
    Pensacola, Florida 32502, United States
  • Clinical Research Site
    Saint Petersburg, Florida 33709, United States
  • Clinical Research Site
    Sunrise, Florida 33351, United States
  • Clinical Research Site
    Tampa, Florida 33634, United States
  • Clinical Research Site
    Trinity, Florida 34655, United States
  • Clinical Research Site
    Augusta, Georgia 30912, United States
  • Clinical Research Site
    Columbus, Georgia 31909, United States
  • Clinical Research Site
    Suwanee, Georgia 30024, United States
  • Clinical Research Site
    Honolulu, Hawaii 92103, United States
  • Clinical Research Site
    Boise, Idaho 83704, United States
  • Clinical Research Site
    Wichita, Kansas 67214, United States
  • Clinical Research Site
    Bangor, Maine 04401, United States
  • Clinical Research Site
    Lowell, Massachusetts 01852, United States
  • Clinical Research Site
    Flint, Michigan 48532, United States
  • Clinical Research Site
    Chesterfield, Missouri 63005, United States
  • Clinical Research Site
    Las Vegas, Nevada 89106, United States
  • Clinical Research Site
    Toms River, New Jersey 08755, United States
  • Clinical Research Site
    Brooklyn, New York 11229, United States
  • Clinical Research Site
    East Syracuse, New York 13057, United States
  • Clinical Research Site
    New Windsor, New York 12553, United States
  • Clinical Research Site
    New York, New York 10036, United States
  • Clinical Research Site
    Charlotte, North Carolina 28211, United States
  • Clinical Research Site
    Hickory, North Carolina 28601, United States
  • Clinical Research Site
    Dayton, Ohio 45459, United States
  • Clinical Research Site
    Jenkintown, Pennsylvania 19046, United States
  • Clinical Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Clinical Research Site
    Austin, Texas 78737, United States
  • Clinical Research Site
    Cypress, Texas 77429, United States
  • Clinical Research Site
    Houston, Texas 77074, United States
  • Clinical Research Site
    McKinney, Texas 75071, United States
  • Clinical Research Site
    Mesquite, Texas 75149, United States
  • Clinical Research Site
    San Antonio, Texas 78229, United States
  • Clinical Research Site
    Sugar Land, Texas 77479, United States
  • Clinical Research Site
    West Jordan, Utah 84088, United States
  • Clinical Research Site
    Woodstock, Vermont 05091, United States
  • Clinical Research Site
    Everett, Washington 98201, United States
  • Clinical Research Site
    Waukesha, Wisconsin 53188, United States
  • Clinical Research Site
    Kelowna, British Columbia V1Y 1Z9, Canada
  • Clinical Research Site
    Newmarket, Ontario L3Y G8, Canada
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Nov 2022, 22 months.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 22 months is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2021
First posted
Mar 15, 2021
StartActual
Dec 31, 2020
Primary completionActual
Nov 21, 2022
CompletionActual
Nov 21, 2022
Results delay requested
Nov 20, 2023
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04797715
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
Dec 31, 2020
Primary completion
Nov 21, 2022
Completion
Nov 21, 2022
Last update
Nov 29, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05

Start the discussion